Search

良性前立腺肥大症患者25例に於いて, 6例にNFLX(ノルフロキサシン), 10例にCPFX(シプロフロキサシン), 5例にTFLX(トスフロキサシン), 4例にENX(エノキサシン), 全例に同時にOFLXを投与した。用量は, TFLXの150mg以外は100mgであった。OFLXの血清中濃度はNFLX, CPFX, TFLX, 或いはENXのそれに比し有意に高かった。OFLXの前立腺組織中濃度はCPFX或いはTFLXのそれに比し有意に高かった。組織/血清中濃度比は各薬物間で有意差がなかった。OFLXの高い組織中濃度は高い血清中濃度によると思われた, Twenty five patients with benign prostate hypertrophy were administered ofloxacin (OFLX) simultaneously with norfloxacin (NFLX) in 6 patients, ciprofloxacin (CPFX) in 10, tosfloxacin (TFLX) in 5 and enoxacin (ENX) in 4 patients. The dose of these new quinolones was 100 mg (except 150 mg of TFLX). Their concentrations in the serum and the prostate tissue were measured by high performance liquid chromatography (HPLC). The serum concentration of OFLX was significantly higher than that of NFLX, CPFX, TFLX or ENX. The prostate tissue concentration of OFLX was significantly higher than that of CPFX or TFLX. The ratio of tissue versus serum concentration of each new quinolone agent was not significantly different. The high OFLX tissue concentration appeared to be caused by the high serum concentration.

経直腸的超音波断層撮影による前立腺体積, アンケート調査による症状, 残尿量, 及びuroflowmetryにより評価した排尿力の間の関係に於いて, BPH(前立腺肥大症)の臨床的特徴に就いて検討した。しかし, これらの間には明らかな関係が認められず, これは, 残尿量の不良な再現性, 症状の列挙困難, 排尿障害が加齢や他の未知因子と相関している他の疾患の不純な混合などによると考えられた。この様な状況下では, この疾患はBPH症候群として取り扱うべきである。更に, BPH症候群は, 1型:前立腺腫大がない症候性BPH, 2型:前立腺腫大を伴う無症候性BPH, 3型:前立腺腫大を伴う症候性BPH, に分類する事を提唱した, Clinical characteristics of BPH were investigated in the relationship among prostate volume estimated by transrectal sonography, symptoms by questionnaire, residual urine volume, and voiding force evaluated by uroflowmetry. There was no apparent relationship among them, which might be caused by the poor reproducibility of residual urine volume, the difficult enumeration of the symptoms, contamination of other diseases of which voiding disorder is correlated with aging and other unknown factors. Under such a situation, this disease should be treated as a BPH syndrome. Moreover we propose that BPH syndrome should be classified into three types; type 1: symptomatic BPH without enlarged prostate, type 2: asymptomatic BPH with enlarged prostate and type 3: symptomatic BPH with enlarged prostate.